OncoTherapeutica, Inc. (OTI) was founded in 2014 by Amin I. Kassis, PhD, Professor of Radiology (Emeritus), Harvard Medical School. Dr. Kassis is a prolific inventor with more than 100 US and world issued/pending patents (most licensed to biotech companies). OTI aims to develop and commercialize proprietary innovative Personalized‐to‐Patient cancer imaging and therapeutic ProDrugs (PD) and technologies licensed from other Institutions.
The initial therapeutics (PD-01 and PD-02), formulated to selectively target and be permanently trapped in lesions of prostate cancer (PC) and malignant melanoma (MM), respectively, are undergoing preclinical Proof-Of-Concept studies (NCI–SBIR funding). Once within a lesion, these PDs transform into toxic drugs that are expected to enhance the well-being of patients experiencing the impact of these devastating disease.
OTI plans to build on these core technologies as models to jump-start its operations and to develop a platform for other therapeutics that will target and concentrate specifically in various types of cancerous lesions.
- Amin Kassis, PhD President & CEO
- Khalid Matalka, PhD Chief Biologist
- Ashfaq Mahmoo, PhD Chief Chemist